SI2098248T1 - Kombinacija antiholinergikov, glukokortikoidov in beta-2-agonistov za zdravljenje vnetnih bolezni - Google Patents

Kombinacija antiholinergikov, glukokortikoidov in beta-2-agonistov za zdravljenje vnetnih bolezni

Info

Publication number
SI2098248T1
SI2098248T1 SI200631387T SI200631387T SI2098248T1 SI 2098248 T1 SI2098248 T1 SI 2098248T1 SI 200631387 T SI200631387 T SI 200631387T SI 200631387 T SI200631387 T SI 200631387T SI 2098248 T1 SI2098248 T1 SI 2098248T1
Authority
SI
Slovenia
Prior art keywords
anticholinergics
glucocorticoids
treatment
agonists
inflammatory diseases
Prior art date
Application number
SI200631387T
Other languages
English (en)
Inventor
Joachim Dr Maus
Horst Kastrup
Peter Jurgen Cnota
Artur Bauhofer
Istvan Szelenyi
Original Assignee
Meda Pharma Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37872413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2098248(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meda Pharma Gmbh & Co Kg filed Critical Meda Pharma Gmbh & Co Kg
Publication of SI2098248T1 publication Critical patent/SI2098248T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SI200631387T 2005-12-21 2006-12-01 Kombinacija antiholinergikov, glukokortikoidov in beta-2-agonistov za zdravljenje vnetnih bolezni SI2098248T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75205805P 2005-12-21 2005-12-21
EP09006788A EP2098248B1 (en) 2005-12-21 2006-12-01 Combination of anticholinergics, glucocorticoids and beta2-agonists for the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
SI2098248T1 true SI2098248T1 (sl) 2012-09-28

Family

ID=37872413

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200631387T SI2098248T1 (sl) 2005-12-21 2006-12-01 Kombinacija antiholinergikov, glukokortikoidov in beta-2-agonistov za zdravljenje vnetnih bolezni
SI200630435T SI1971369T1 (sl) 2005-12-21 2006-12-01 Kombinacija R,R-glikopirolata,roliprama in budezonida za zdravljenje vnetnih bolezni

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200630435T SI1971369T1 (sl) 2005-12-21 2006-12-01 Kombinacija R,R-glikopirolata,roliprama in budezonida za zdravljenje vnetnih bolezni

Country Status (20)

Country Link
US (2) US8048910B2 (sl)
EP (2) EP1971369B1 (sl)
JP (1) JP5107933B2 (sl)
CN (1) CN101321539B (sl)
AT (1) ATE439834T1 (sl)
AU (1) AU2006329042B2 (sl)
CA (2) CA2632780C (sl)
CY (2) CY1110519T1 (sl)
DE (1) DE602006008665D1 (sl)
DK (2) DK1971369T3 (sl)
ES (2) ES2330047T3 (sl)
HK (1) HK1123497A1 (sl)
HR (2) HRP20090498T1 (sl)
NO (1) NO20083090L (sl)
NZ (2) NZ568349A (sl)
PL (2) PL1971369T3 (sl)
PT (2) PT2098248E (sl)
RU (1) RU2465915C2 (sl)
SI (2) SI2098248T1 (sl)
WO (1) WO2007071313A2 (sl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2413011T3 (es) * 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
PL2068889T3 (pl) * 2006-08-10 2020-06-29 Roy C. Levitt Anakinra do zastosowania do leczenia zespołu zarostowego zapalenia oskrzelików
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
US9623000B2 (en) 2008-07-31 2017-04-18 Dekel Pharmaceuticals Ltd Compositions and methods for treating inflammatory disorders
CN101474191B (zh) * 2009-01-21 2011-03-23 李虎山 一种治疗哮喘和慢性阻塞性肺病的药物组合物
CN107412212B (zh) 2009-05-29 2021-01-22 珍珠治疗公司 经肺递送长效毒蕈碱拮抗剂及长效β2肾上腺素能受体激动剂的组合物及相关方法与系统
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2010258751A1 (en) * 2009-06-09 2012-02-02 Sunovion Respiratory Development Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
GEP20156311B (en) 2009-12-23 2015-07-10 Chiesi Farma Spa Combination therapy for copd
CN107308161A (zh) 2010-06-16 2017-11-03 炎症反应研究股份有限公司 左西替利嗪和孟鲁司特在治疗流感、普通感冒和炎症中的用途
US20120077786A1 (en) * 2010-09-27 2012-03-29 Byron David A Methods and compositions for disease treatment using inhalation
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
US10179139B2 (en) 2010-10-12 2019-01-15 Cipla Limited Pharmaceutical composition
WO2012107364A1 (en) * 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
CN102247380A (zh) * 2011-08-19 2011-11-23 北京阜康仁生物制药科技有限公司 一种以布地奈德与茚达特罗为活性成分的复方制剂
LT2948148T (lt) * 2013-01-28 2020-12-28 Incozen Therapeutics Pvt. Ltd. Autoimuninių, kvėpavimo ir uždegiminių sutrikimų gydymo būdai, įkvėpiant roflumilasto n-oksidą
CN105228700A (zh) * 2013-03-13 2016-01-06 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗自身免疫病中的用途
AU2014249531B2 (en) 2013-03-13 2018-11-29 IRR, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
CN105263579B (zh) 2013-03-13 2020-01-10 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗血管炎中的用途
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
US10058661B2 (en) 2014-12-04 2018-08-28 Norton (Waterford) Limited Inhalation monitoring system and method
JP6528314B2 (ja) * 2015-03-20 2019-06-12 国立大学法人山口大学 Ａ（Ｈ１Ｎ１）ｐｄｍ０９インフルエンザウイルス感染による気管支喘息の予防又は改善剤
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
CN111228257A (zh) * 2020-03-03 2020-06-05 中国人民解放军南部战区总医院 咯利普兰在制备治疗脓毒症心功能障碍的药物中的应用
EP4209219A1 (en) * 2022-01-07 2023-07-12 MetrioPharm AG Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100331255B1 (ko) * 1993-07-02 2002-10-25 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 플루오로알콕시-치환된벤즈아미드및시클릭뉴클레오티드포스포디에스테라아제억제제로서의그의용도
EP0932401A1 (en) 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
DK0937041T3 (da) * 1996-11-11 2003-08-11 Christian R Noe Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6402285B1 (en) * 1998-05-29 2002-06-11 Citizen Watch Co., Ltd. Method of subjecting ink jet printer to preuse treatment
CN1150890C (zh) 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
DK1131059T3 (da) * 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
US6745467B1 (en) * 1999-02-10 2004-06-08 Canon Kabushiki Kaisha Method of producing a liquid discharge head
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6086914A (en) * 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
GB9918760D0 (en) * 1999-08-09 1999-10-13 Darwin Discovery Ltd Topical treatment
US20040028958A1 (en) 2002-06-18 2004-02-12 Total Innovative Manufacturing Llc Recyclable fire-resistant moldable batt and panels formed therefrom
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
JP4824267B2 (ja) 2001-03-30 2011-11-30 ヤゴテック アーゲー 医療用エアゾール配合物
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
JP2004530705A (ja) 2001-05-25 2004-10-07 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 閉塞性気道疾患及びその他の炎症性疾患を治療するためのｐｄｅ４インヒビター及びチオトロピウム又はその誘導体の組み合わせ
OA12610A (en) 2001-05-25 2006-06-09 Pfizer A PDE 4 inhbitor and an anti-cholinergic agent in combination for treating obstructive airways diseases.
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US7258118B2 (en) * 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US20050107420A1 (en) * 2002-05-23 2005-05-19 Boehringe Ingelheim Pharma Gmbh & Co. Kg Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases
US20040038958A1 (en) * 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) * 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
EP2319582A1 (en) * 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising formoterol, budesonide and tiotropium or oxitropium
US20040053902A1 (en) * 2002-09-13 2004-03-18 Smith C. Steven Novel composition and method for treatment of upper respiratory conditions
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US20060189642A1 (en) 2003-03-28 2006-08-24 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
EP1610787B1 (en) * 2003-03-28 2008-01-23 Nycomed GmbH Synergistic combination comprising roflumilast and an anticholinergic agent selected from tiotropium salts for the treatment of respiratory diseases
EP1646881A1 (en) 2003-07-11 2006-04-19 Philips Intellectual Property & Standards GmbH Improved frequency determination
AU2004311478A1 (en) * 2003-12-31 2005-07-21 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
PL1718336T3 (pl) * 2004-02-06 2008-11-28 Meda Pharma Gmbh & Co Kg Nowe połączenie środków antycholinergicznych i beta-mimetyków do leczenia chorób układu oddechowego
ES2413011T3 (es) * 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
WO2005074983A2 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
EP1720577A2 (en) * 2004-02-27 2006-11-15 Altana Pharma AG Ciclesonide and glycopyrronium combination
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
DE102004056579A1 (de) * 2004-11-23 2006-05-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Salmeterol und ein Steroid
EP1879620A2 (en) * 2005-03-30 2008-01-23 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases

Also Published As

Publication number Publication date
JP2009520711A (ja) 2009-05-28
PL1971369T3 (pl) 2010-01-29
NZ568349A (en) 2011-05-27
RU2008129600A (ru) 2010-01-27
JP5107933B2 (ja) 2012-12-26
US8518918B2 (en) 2013-08-27
SI1971369T1 (sl) 2009-12-31
ES2389231T3 (es) 2012-10-24
EP1971369A2 (en) 2008-09-24
CN101321539A (zh) 2008-12-10
ATE439834T1 (de) 2009-09-15
DK1971369T3 (da) 2009-11-16
WO2007071313A2 (en) 2007-06-28
CA2632780A1 (en) 2007-06-28
US20120076739A1 (en) 2012-03-29
ES2330047T3 (es) 2009-12-03
CN101321539B (zh) 2010-09-29
AU2006329042B2 (en) 2012-02-02
EP1971369B1 (en) 2009-08-19
HK1123497A1 (en) 2009-06-19
US8048910B2 (en) 2011-11-01
PT2098248E (pt) 2012-08-27
EP2098248A1 (en) 2009-09-09
DK2098248T3 (da) 2012-09-17
RU2465915C2 (ru) 2012-11-10
CY1113080T1 (el) 2016-04-13
HRP20090498T1 (en) 2009-10-31
DE602006008665D1 (de) 2009-10-01
WO2007071313A3 (en) 2007-10-11
EP2098248B1 (en) 2012-06-06
NO20083090L (no) 2008-09-11
PT1971369E (pt) 2009-10-20
CY1110519T1 (el) 2015-04-29
CA2824075A1 (en) 2007-06-28
US20070196285A1 (en) 2007-08-23
NZ591969A (en) 2012-05-25
HRP20120708T1 (hr) 2012-10-31
AU2006329042A1 (en) 2007-06-28
PL2098248T3 (pl) 2012-11-30
CA2824075C (en) 2015-04-28
CA2632780C (en) 2013-11-12

Similar Documents

Publication Publication Date Title
SI2098248T1 (sl) Kombinacija antiholinergikov, glukokortikoidov in beta-2-agonistov za zdravljenje vnetnih bolezni
TW200708513A (en) Novel crystalline forms of tiotropium bromide
WO2006117300A3 (en) Crystalline forms of tiotropium bromide
JP2010516662A5 (sl)
WO2007082068A3 (en) Methods and compositions for treating asthma in human and non human primates
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
WO2005070891A3 (en) Compounds and methods of use
WO2011158042A3 (en) Ureido- pyrazole derivatives for use in the treatment of rhinovirus infections
HK1146485A1 (sl)
MX2014000338A (es) Derivados de pirrolo-pirimidina novedoso.
WO2008155069A3 (de) Substituierte oxazolidinone und ihre verwendung
MX2009009443A (es) Compuestos de pirimidina hidrazida como inhibidores de pgds.
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
MY160471A (en) New ccr2 receptor antagonists and uses thereof
WO2011021203A3 (en) Desferrioxamine-metal complexes for the treatment of immune-related disorders
WO2007062318A3 (en) Chemical compounds
WO2009092052A3 (en) Methods and compositions for treating polyps
WO2010080757A3 (en) Combinations with an alpha-4beta-2 nicotinic agonist
EP2120935A4 (en) NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA
WO2006086609A3 (en) Inhibitors of tryptase
EP2125728A4 (en) NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA
MX2010002116A (es) Un modulador de nrg1 para el tratamiento de trastornos respiratorios.
EP2216052A4 (en) USE OF A NEW COMPOUND WITH AFFINITY FOR AMYLOID AND METHOD FOR THE PRODUCTION THEREOF
WO2010048384A3 (en) Arformoterol and tiotropium compositions and methods for use
WO2010025436A3 (en) Nitrogen and sulfur-containing heterocycle derivatives